


Crohn's MAP Vaccine

Professor John Hermon-Taylor
Division of Diabetes and Nutritional Sciences
Franklin-Wilkins Building King's College London SE1 9NH UK

General Enquiries: info@crohnsmapvaccine.com
Media Enquiries: media@crohnsmapvaccine.com
www.crohnsmapvaccine.com



Media Release: 10 June 2015

'Manufacturing To Begin On Groundbreaking Crohn's Disease Vaccine'

Manufacturing at Oxford University's Clinical BioManufacturing Facility will soon begin on a ground breaking vaccine for the chronic illness Crohn's disease, which could potentially change the lives of millions of sufferers worldwide.

The vaccine, co-developed by Professor John Hermon-Taylor (King's College London) and Professor Sarah Gilbert (Jenner Institute, Oxford), is based on research which shows the disease could be caused by a bacterium known as MAP (Mycobacterium avium subspecies paratuberculosis). MAP is the proven cause of Johne's disease – a form of inflammatory bowel disease strikingly similar to Crohn's – in cattle.

The MAP vaccine is a modern therapeutic vaccine; it is designed to treat the disease by stimulating the body's immune system to produce T-cells (a type of white blood cell) which recognise and eradicate MAP. Manufacture is due to begin in October 2015, with Phase I trials planned for late 2016 and Phase II trials to follow in 2017 before potentially becoming available to treat patients in just a few years.

Prof. Hermon-Taylor said: "I have been researching MAP and its relationship to Crohn's Disease for over 30 years. On the basis of what I have seen I believe it to be the predominant cause of Crohn's disease."

Research suggests that MAP is most commonly passed to humans through cows' milk and other dairy products, meat and contaminated water supplies. Crohn's disease can have a debilitating impact on sufferers' lives and a vaccine could bring hope to millions worldwide.

Prof. Hermon-Taylor added: "Clinical studies of the vaccine in mice and in cattle have shown it to be highly effective against MAP with no obvious adverse effects. Now we need to spread the word, to raise awareness and the funding for human trials."

With the new, more sensitive MAP test Prof. Hermon-Taylor is currently developing, 100% of Crohn's sufferers studied to date have tested positive for MAP, suggesting that a vaccine could have a significant impact on future treatment of the disease. Researchers are appealing for donations and investment to continue funding for trials and manufacturing.

For more information, or to contribute to funding the MAP vaccine trials, visit crohnsmapvaccine.com, [facebook.com/crohnsmapvaccine](https://www.facebook.com/crohnsmapvaccine) or contact info@crohnsmapvaccine.com

What is Crohn's Disease?

Crohn's Disease is a debilitating and aggressive form of Inflammatory Bowel Disease. It affects probably around 4 million worldwide, including 1.2 million in the USA and reportedly around 250,000 in the UK - and numbers are increasing, especially in children.

Symptoms include chronic severe abdominal pain, weight loss, bloody diarrhoea and fatigue. Up to 80% of patients will need surgery at some point in their lifetime.

There is currently no cure and the lives of most sufferers are blighted by multiple hospitalisations, surgeries, immunosuppressive therapies (and their side effects) and difficulty holding down a job or attending school.



BRAVE CROHN'S SUFFERER URHO, AGE 7